Axamon® (ipidacrine) - cholinesterase inhibitor. Axamon stimulates neuromuscular transmission and conduction of excitation along the nerve and smooth muscles due to blockage of the potassium channels of the excitable membrane and inhibition of cholinesterase activity, enhances the effect on the smooth muscles of acetylcholine, serotonin, histamine, oxytocin, but not potassium chloride.
Indications for use:
Dosage and administration
Orally. Doses and duration of treatment are determined individually depending on the on the patient’s condition.
Typically, axamon is prescribed at 10-20mg 2-3 times a day. The maximum daily dose is up to 200mg. The duration of treatment is from 1 month to 1 year.
For the treatment of the peripheral nervous system diseases, myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.For the treatment of the Alzheimer's disease, encephalopathy, the recovery period of organic diseases of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis: the daily dose is selected individually, usually 10-20 mg 2-3 times a day.With demyelinating lesions of the nervous system, the dose can be increased to 20-40 mg 5-6 times a day.
Anorexia, hypersalivation, nausea, vomiting, increased peristalsis, diarrhea, jaundice, dizziness (after repeated administration), ataxia, skin itch, rash, manifestations of M-anticholinergic action - bronchospasm, bradycardia.
Hypersensitivity, epilepsy, estrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, tendency to vistibular disorders, pregnancy, lactation.